

IN THE CLAIMS

Please cancel claims 1-19 without prejudice or disclaimer. Please add the claims set forth below.

Claims 1-19. (Cancelled).

Claim 20. (New) A modified Factor VIII polypeptide having a Factor VIII:C activity, wherein the modified Factor VIII polypeptide has at least one modification in at least one A3 domain portion, wherein the portion is selected from the group of portions consisting of amino acids (i) 1743 (Phe) to 1749 (Arg), (ii) 1784 (Ser) to 1831 (Asp), (iii) 1888 (Ser) to 1919 (His), (iv) 1942 (Trp) to 1947 (Met), and (v) 1959 (Ser) to 1974 (Ala), wherein the modification is an amino acid substitution, deletion or addition, and wherein the modification reduces the binding to low-density lipoprotein receptor protein (LRP).

Claim 21. (New) The modified Factor VIII polypeptide of claim 20, wherein the modified Factor VIII polypeptide further comprises at least one modification in at least one C1 domain portion, wherein the portion is selected from the group of portions consisting of amino acids (i) 2037 (Ile) to 2062 (Trp), (ii) 2108 (Asp) and 2118 (Asn), and (iii) 2154 (Thr) to 2158 (Ile), wherein the modification is an amino acid substitution, deletion or addition.

Claim 22. (New) The modified Factor VIII polypeptide of claim 20, wherein the modified Factor VIII polypeptide further comprises at least one modification in at least one C2 domain portion, wherein the portion is selected from the group of portions consisting of amino acids (i) 2209 (Arg) to 2234 (Phe) and (ii) 2269 (His) to 2281 (Lys), wherein the modification is an amino acid substitution, deletion or addition.

Claim 23. (New) The modified Factor VIII polypeptide of claim 20, wherein the modified Factor VIII polypeptide is produced by recombinant techniques.

Claim 24. (New) A preparation comprising:

- (A) a modified Factor VIII polypeptide having a Factor VIII:C activity, wherein the modified Factor VIII polypeptide has at least one modification in at least one A3 domain portion, wherein the portion is selected from the group of portions consisting of amino acids (i) 1743 (Phe) to 1749 (Arg), (ii) 1784 (Ser) to 1831 (Asp), (iii) 1888 (Ser) to 1919 (His), (iv) 1942 (Trp) to 1947 (Met), and (v) 1959 (Ser) to 1974 (Ala), wherein the modification is an amino acid substitution, deletion or addition, and wherein the modification reduces the binding to low-density lipoprotein receptor protein (LRP); and
- (B) a lipoprotein receptor protein antagonist.

Claim 25. (New) The preparation according to claim 24, wherein the lipoprotein receptor protein antagonists are selected from the group consisting of receptor-

associated protein (RAP) and a fragment of lipoprotein receptor protein from clusters I, II, III or IV, wherein the fragment binds to a Factor VIII-LRP binding site

Claim 26. (New) The preparation according to claim 24, wherein the modified Factor VIII polypeptide further comprises at least one modification in at least one C1 domain portion, wherein the portion is selected from the group of portions consisting of amino acids (i) 2037 (Ile) to 2062 (Trp), (ii) 2108 (Asp) and 2118 (Asn), and (iii) 2154 (Thr) to 2158 (Ile), wherein the modification is an amino acid substitution, deletion or addition.

Claim 27. (New) The preparation according to claim 24, wherein the modified Factor VIII polypeptide further comprises at least one modification in at least one C2 domain portion, wherein the portion is selected from the group of portions consisting of amino acids (i) 2209 (Arg) to 2234 (Phe) and (ii) 2269 (His) to 2281 (Lys), wherein the modification is an amino acid substitution, deletion or addition.

28. (New) The preparation of claim 24, wherein the modified Factor VIII polypeptide is produced by recombinant techniques.